ClinicalTrials.gg
CompletedNCT06905847Updated Apr 2, 2025

Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Primary Efficacy of HSK39004 Suspension for Inhalation

A Phase 1 interventional study of HSK39004 in healthy and HSK39004 in Healthy Donors, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-02.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Sep 2024, registered Dec 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

To evaluate the safety, tolerability and pharmacokinetic characteristics of HSK39004 suspension for inhalation in single/multiple administration(s) in healthy subjects; to evaluate the safety,tolerability and efficacy of HSK39004 suspension for inhalation in multiple administrations in patients with Chronic Obstructive Pulmonary Disease(COPD).

02

Conditions studied

  • Healthy Donors
03

In context

Lead sponsor

Haisco Pharmaceutical Group Co., Ltd. is the lead sponsor of 118 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For healthy volenteers:

    1. Voluntarily sign the form, understand the trialprocedures, and be willing to comply with all trial procedures andrestrictions;
    2. 18 years to 45 years (inclusive), male and female;
    3. Male subjects weight ≥50 kg and female subjects weight ≥45 kg. (BMI) : 18-26 kg/m2 (inclusive) ;
    4. Ability to perform acceptable and reproducible spirometry;
    5. Normal lung function during the screening period, no airway obstruction, and forced vital capacity(FVC) are at least 80% of the predicted values;
    6. Subjects are willing to voluntarily use effectivecontraceptives from screening to at least 3 months after the last dose administration.
  • For patients:

    1. Voluntarily sign the informed consent form, understand the trialprocedures, and be willing to comply with all trial procedures andrestrictions;
    2. Age ≥ 40 years , male and female;
    3. According to the diagnostic criteria of 2024 Practical Edition of Guidelines , the patient was diagnosed with COPD; The patient has chronic respiratory symptoms such as shortness of breath, chronic cough or expectoration, and/or a history of exposure to risk factors, and the results of pulmonary function tests show that post-bronchodilator spirometry demonstrate FEV1/FVC ratio of ≤0.70 ;
    4. At screening: post-bronchodilator spirometry demonstrate FEV1/FVC ratio of ≤0.70 and FEV1 must be ≥40 % to ≤80% of predicted normal and FEV1 increased by ≥100ml compared with pre-bronchiectasis;
    5. No regular treatment of COPD was performed before joining the study. COPD agents (except SABA and/or SAMA) that are in the protocol may be discontinued during the screening and treatment;
    6. Subjects are willing to voluntarily use effectivecontraceptives from screening to at least 3 months after the last dose administration.

Exclusion criteria

Exclusion Criteria:

  • For healthy volenteers:

    1. Have a history of severe and uncontrolled diseases, such ascardiovascular, respiratory, liver, gastrointestinal, endocrine,hematologic, mental/nervous systems diseases within 3 months prior to screening;
    2. Have a history of any malignant tumors;
    3. Normal or abnormal vital signs, physical examination, laboratory examination, , and imageological examination have no clinical significance (only for healthy subjects);
    4. Previous or current gastrointestinal, liver, kidney, or other disease known to interfere with drug absorption, distribution, metabolism, or excretion;
    5. Acute respiratory infections occurred within 6 weeks before screening and/or before randomization;
    6. Have a history of high consumption of grapefruit juice, methylxanthinerich food or beverage (such as coffee, tea, cola, chocolate, energydrinks) ,consumption of grapefruit juice, methylxanthine-rich food within 48 hours before the administration;
    7. Smoking more than 5 cigarettes per day within 3 months prior toscreening or smoking during the study (only for healthy subjects);
    8. Average alcohol intake is more than 14 unit per week (1unit=10g alcohol , 1 unit=285 mL 4.9% alcohol beer, or 30 mL 40% alcohol spirit, or 100mL 12% alcohol wine) within the 3 months prior to screening;
    9. Have a history of drug abuse prior to screening, or positive urine drug screen at screening (If patients were false positives due to other medications, they can be retested after the medication is washed);
    10. Blood donation (or blood loss) ≥400 mL within 3 months prior to the screening;
    11. Subjects who have a allergic to any component of HSK39004 or allergic history to opiates;
    12. Intolerance to this product or the same target drug;
    13. Subjects who use any within 30 days prior to screening;
    14. Have participated in any clinical investigator within 3 months prior to screening;
    15. A pregnant/lactating woman, or has a positive pregnancy test at screening or during the trial;
    16. Not suitable for this study as judged by the investigator.
  • For COPD patients, in addition to meeting the above exclusion criteria, they should also:

    1. Present with any of the following diseases: Alpha-1 antitrypsin deficiency, asthma, active pulmonary tuberculosis, lung cancer, pulmonary edema, cystic fibrosis, bronchiolitis obliterans, sarcoidosis (sarcoidosis), bronchiectasis, unstable sleep apnea, Or pulmonary fibrosis, pulmonary hypertension, or interstitial lung disease determined by the study physician to be a safety risk to the patient and/or to affect the analysis of the study results;
    2. Previous or current history of serious cardiovascular disease;
    3. Have type 1 diabetes or poorly controlled type 2 diabetes (fasting blood glucose ≥10 mmol/L at screening);
    4. During the screening period, the investigators determined that the patient's laboratory tests had clinically significant abnormalities that could pose a safety risk to the patient;
    5. Patients who were hospitalized for COPD or infectious pneumonia within 8 weeks prior to screening and/or had acute exacerbations of COPD or infectious pneumonia between the screening period and prior to randomization, indicating the presence of an active infection;
    6. Patients with acute exacerbations of moderate to severe COPD ≥2 times/year within 1 year before screening;
    7. Acute exacerbations of COPD requiring treatment with oral or parenteral occurred within 8 weeks prior to screening;
    8. Had lung volume reduction surgery within 1 year prior to lung resection or screening;
    9. Patients who use oxygen therapy for long-trem and more than 12 hours per day;
    10. Not suitable for this study as judged by the investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    HSK39004 in healthy volenteers

    Single or multiple inhaled HSK39004

    Drug: HSK39004 in healthy

  • Placebo comparator
    Placebo

    Placebo

    Drug: HSK39004

  • Experimental
    HSK39004 in COPD patients

    multiple inhaled HSK39004

    Drug: HSK39004 in COPD

Interventions

06

What researchers measure

Primary outcomes

  1. adverse events

    The Incidence of adverse events as assessed by CTCAE v5.0

    Time frame: From the enrollment of the subjects to 72 hours after the last administration

Secondary outcomes

  1. AUC

    area under the concentration-time curve

    Time frame: from 0 to 72 hours after administration

  2. Cmax

    maximum plasma concentration

    Time frame: from 0 to 72 hours after administration

  3. t1/2

    half-life

    Time frame: from 0 to 72 hours after administration

  4. Vz/F

    apparent volume of distribution

    Time frame: from 0 to 72 hours after administration

  5. CL/F

    apparent clearance

    Time frame: from 0 to 72 hours after administration

  6. Forced Expiratory Volume in the first second (FEV1) for patients with COPD

    Mean Change From Baseline in Peak FEV1, Mean Change From Baseline FEV1 to Morning Trough FEV1

    Time frame: From 0 before first administration to 24 hours after last administration

07

Study locations

1 site
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610044, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2024 to primary completion in Jan 2025, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 31, 2024
First posted
Apr 2, 2025
StartActual
Sep 2, 2024
Primary completionActual
Jan 13, 2025
CompletionActual
Mar 20, 2025
Last update
Apr 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06905847
Responsible party
Sponsor
First posted
Apr 2, 2025
Start date
Sep 2, 2024
Primary completion
Jan 13, 2025
Completion
Mar 20, 2025
Last update
Apr 2, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HSK39004

Start the discussion